Profile data is unavailable for this security.
About the company
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
- Revenue in TWD (TTM)14.17bn
- Net income in TWD3.19bn
- Incorporated2007
- Employees91.00
- LocationBora Pharmaceuticals Co Ltd6F, No.2, Alley 36, Lane 26, Ruiguang RoTAIPEI 114TaiwanTWN
- Phone+886 227901555
- Fax+886 227906595
- Websitehttps://www.bora-corp.com/
Mergers & acquisitions
| Acquired company | 6472:TAI since announced | Transaction value |
|---|---|---|
| Upsher-Smith Laboratories LLC | 17.61% | -- |
| Sawai America Holdings Inc | 10.66% | 210.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ScinoPharm Taiwan Ltd | 3.43bn | 403.00m | 20.01bn | 1.01k | 49.76 | 1.93 | 22.87 | 5.84 | 0.5084 | 0.5084 | 4.33 | 13.12 | 0.2871 | 1.27 | 6.63 | -- | 3.37 | 2.33 | 3.69 | 2.51 | 38.89 | 41.09 | 11.76 | 9.10 | 5.00 | -- | 0.0592 | 109.25 | -2.39 | -2.00 | -18.73 | -8.31 | 16.90 | -9.35 |
| Lotus Pharmaceutical Co Ltd | 16.93bn | 4.01bn | 74.74bn | 1.10k | 18.43 | 4.04 | 14.22 | 4.41 | 15.27 | 15.27 | 64.44 | 69.72 | 0.5107 | 1.99 | 2.62 | -- | 12.10 | 9.17 | 15.23 | 11.36 | 54.64 | 49.32 | 23.70 | 15.99 | 1.58 | -- | 0.366 | 26.77 | 15.89 | 21.41 | 35.91 | 110.44 | 52.35 | -- |
| Bora Pharmaceuticals Co Ltd | 14.17bn | 3.19bn | 77.99bn | 91.00 | 25.07 | 8.08 | 19.20 | 5.51 | 30.64 | 30.64 | 134.98 | 95.05 | 0.4418 | 2.12 | 2.16 | -- | 10.25 | 11.27 | 21.59 | 18.66 | 47.99 | 39.25 | 23.19 | 18.55 | 0.9497 | 5.53 | 0.6005 | 37.82 | 35.31 | 59.57 | 117.70 | 46.91 | 128.20 | 64.83 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 08 Aug 2024 | 2.12m | 2.09% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.34m | 1.32% |
| Fuh Hwa Securities Investment Trust Co., Ltd.as of 30 Jun 2024 | 1.32m | 1.30% |
| BlackRock Fund Advisorsas of 08 Aug 2024 | 627.11k | 0.62% |
| Dimensional Fund Advisors LPas of 08 Aug 2024 | 393.43k | 0.39% |
| Capital Investment Trust Corp.as of 30 Jun 2024 | 340.00k | 0.34% |
| Uni-President Asset Management Corp.as of 30 Jun 2024 | 200.00k | 0.20% |
| Victory Capital Management, Inc. (Investment Management)as of 30 Jun 2024 | 168.00k | 0.17% |
| Taishin Securities Investment Trust Co., Ltd.as of 30 Jun 2024 | 149.00k | 0.15% |
| BlackRock Advisors (UK) Ltd.as of 08 Aug 2024 | 138.60k | 0.14% |
